ROCKVILLE, Md.--(BUSINESS WIRE)--The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded ABL with a contract to provide preclinical development support for promising candidates when such candidates emerge from the investigator-initiated research studies. These capabilities will allow NIAID to more rapidly and efficiently close development and production gaps. ABL will assist NIAID staff in providing all support needed for smallscale production, preclinical testing and documentation leading to Investigational New Drug (IND) submissions for Phase I, II and III clinical testing. This work is funded in whole with federal funds from NIAID, NIH, Department of Health and Human Services, under Contract Number HHSN272201100021I.
